WO2000028039A3 - Identification of senv genotypes - Google Patents

Identification of senv genotypes Download PDF

Info

Publication number
WO2000028039A3
WO2000028039A3 PCT/EP1999/008566 EP9908566W WO0028039A3 WO 2000028039 A3 WO2000028039 A3 WO 2000028039A3 EP 9908566 W EP9908566 W EP 9908566W WO 0028039 A3 WO0028039 A3 WO 0028039A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid molecule
genome
virus
viruses
Prior art date
Application number
PCT/EP1999/008566
Other languages
French (fr)
Other versions
WO2000028039A2 (en
Inventor
Daniele Primi
Gianfranco Fiordalisi
Giovanni Lorenzo Mantero
Sonia Mattioli
Alessandra Sottini
Fabrizio Bonelli
Laura Vaglini
Paolo Olivero
Corso Andrea Dal
Marco Bonelli
Original Assignee
Diasorin International Inc
Daniele Primi
Gianfranco Fiordalisi
Giovanni Lorenzo Mantero
Sonia Mattioli
Alessandra Sottini
Fabrizio Bonelli
Laura Vaglini
Paolo Olivero
Corso Andrea Dal
Marco Bonelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI982437 external-priority patent/IT1303732B1/en
Priority claimed from ITMI990923 external-priority patent/IT1312552B1/en
Application filed by Diasorin International Inc, Daniele Primi, Gianfranco Fiordalisi, Giovanni Lorenzo Mantero, Sonia Mattioli, Alessandra Sottini, Fabrizio Bonelli, Laura Vaglini, Paolo Olivero, Corso Andrea Dal, Marco Bonelli filed Critical Diasorin International Inc
Priority to EP99971855A priority Critical patent/EP1137779A2/en
Priority to JP2000581206A priority patent/JP2002529092A/en
Priority to AU13816/00A priority patent/AU1381600A/en
Publication of WO2000028039A2 publication Critical patent/WO2000028039A2/en
Publication of WO2000028039A3 publication Critical patent/WO2000028039A3/en
Priority to NO20012276A priority patent/NO20012276L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to a nucleic acid molecule representing the genome of a virus/viral agent, said nucleic acid molecule having at least one of the following features: (a) it contains at least one open reading frame (ORF) which encodes a polypeptide having an amino acid sequence disclosed herein; (b) it comprises a DNA sequence as described herein; (c) it hybridizes preferably under stringent conditions to the complementary strand of the nucleic acid molecule described herein, but not to the complementary strand of the genome of TT virus; (d) it is degenerate with respect to the hybridizing nucleic acid molecule; (e) it is at least 60 % identical with the nucleic acid molecule representing the genome of the virus/viral agent of the invention; and (f) parts of it can be amplified under suitable conditions by PCR employing primers as defined herein. The invention further relates to vectors comprising said nucleic acid molecule, methods of producing (poly)peptide(s) encoded by said nucleic acid molecule, to viruses/viral agents carrying a genome represented by said nucleic acid molecule and antibodies to said (poly)peptide(s) and/or said viruses/viral agents. Additionally, the invention relates to compositions, preferably pharmaceutical compositions, vaccines, diagnostics and diagnostic kits comprising or employing the compounds of the invention.
PCT/EP1999/008566 1998-11-10 1999-11-09 Identification of senv genotypes WO2000028039A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99971855A EP1137779A2 (en) 1998-11-10 1999-11-09 Identification of senv genotypes
JP2000581206A JP2002529092A (en) 1998-11-10 1999-11-09 Identification of SENV genotype
AU13816/00A AU1381600A (en) 1998-11-10 1999-11-09 Identification of senv genotypes
NO20012276A NO20012276L (en) 1998-11-10 2001-05-09 Identification of SENV genotypes

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
ITMI982437 IT1303732B1 (en) 1998-11-10 1998-11-10 Nucleic acids representing the genome of the SEN virus (SENV) and encoded proteins, useful for treatment of hepatopathies, inflammatory diseases and proliferative disorders such as cancer
ITMI98A002437 1998-11-10
ITMI990923 IT1312552B1 (en) 1999-04-30 1999-04-30 Nucleic acids representing the genome of the SEN virus (SENV) and encoded proteins, useful for treatment of hepatopathies, inflammatory diseases and proliferative disorders such as cancer
ITMI99A000923 1999-04-30
EP99830298 1999-05-14
EP99830298.8 1999-07-16
EP99113932 1999-07-16
EP99113932.0 1999-07-16

Publications (2)

Publication Number Publication Date
WO2000028039A2 WO2000028039A2 (en) 2000-05-18
WO2000028039A3 true WO2000028039A3 (en) 2000-10-05

Family

ID=27443821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/008566 WO2000028039A2 (en) 1998-11-10 1999-11-09 Identification of senv genotypes

Country Status (8)

Country Link
EP (1) EP1137779A2 (en)
JP (1) JP2002529092A (en)
AR (1) AR021143A1 (en)
AU (1) AU1381600A (en)
NO (1) NO20012276L (en)
PE (1) PE20001331A1 (en)
TN (1) TNSN99210A1 (en)
WO (1) WO2000028039A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010034018A1 (en) * 1999-12-10 2001-10-25 Jen-Kuei Liu Hepatitis virus sentinel virus I (SVI)
DE10007234A1 (en) * 2000-02-17 2001-10-18 Sension Biolog Detektions Und Peptide and nucleic acid coding therefor for the determination, diagnosis and therapy of diseases of the nervous system
DE10144346A1 (en) * 2001-09-10 2003-04-03 Deutsches Krebsforsch TT virus sequences in human tumor tissues, means for their detection and tumor therapy
US9676828B2 (en) 2010-06-23 2017-06-13 Deutsches Krebsforschungszentrum Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
US20110318363A1 (en) 2010-06-23 2011-12-29 Deutsches Krebsforschungszentrum Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
EP2399928B1 (en) * 2010-06-23 2017-11-08 Deutsches Krebsforschungszentrum Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
WO2011160848A1 (en) * 2010-06-23 2011-12-29 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechtes Rearranged tt virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005282A1 (en) * 1997-07-25 1999-02-04 Tamura, Ryoji Non-b non-c non-g hepatitis virus gene, polynucleotide, polypeptide, virion, method for separating virion, and method for detecting virus
WO1999058638A2 (en) * 1998-05-13 1999-11-18 Innogenetics N.V. Sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005282A1 (en) * 1997-07-25 1999-02-04 Tamura, Ryoji Non-b non-c non-g hepatitis virus gene, polynucleotide, polypeptide, virion, method for separating virion, and method for detecting virus
WO1999058638A2 (en) * 1998-05-13 1999-11-18 Innogenetics N.V. Sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBAN 5 August 1998 (1998-08-05), YUSEN ET AL.: "Cloning and sequencing of a TT virus from a Chinese patient with hepatitis", XP002141067 *
KHUDYAKOV ET AL.: "Sequence heterogeneity of TT virus and closely related viruses", J. VIROL., vol. 74, no. 7, 2000, pages 2990 - 3000, XP002141066 *
OKAMOTO ET AL.: "Molecular cloning and characterisation of a novel DNA virus (TTV) associated with post-transfusion hepatitis of unknown etiology", HEPATOLOGY RESEARCH, vol. 10, 1998, pages 1 - 16, XP002080816 *
TAKAHASHI ET AL.: "Partial 2.4kb sequences of TT virus (TTV) genome from eight Japanese isolates: diagnostic and phylogenetic implications", HEPATOLOGY RESEARCH, vol. 12, 1998, pages 111 - 120, XP000914984 *

Also Published As

Publication number Publication date
PE20001331A1 (en) 2000-12-19
AU1381600A (en) 2000-05-29
NO20012276D0 (en) 2001-05-09
NO20012276L (en) 2001-07-09
WO2000028039A2 (en) 2000-05-18
TNSN99210A1 (en) 2005-11-10
AR021143A1 (en) 2002-06-12
JP2002529092A (en) 2002-09-10
EP1137779A2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
BE2014C050I2 (en) Circovirus sequences associated with piglet weight loss disease (PWD)
CA2154023A1 (en) Recombinant infectious non-segmented negative strand rna virus
CA2196555A1 (en) Vr-2332 viral nucleotide sequence and methods of use
JP2004511201A5 (en)
WO2001039797A3 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
ZA979732B (en) Infectious clones of RNA viruses and vaccines and diagnostic assays derived therof.
EP1004670A3 (en) Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
WO1992019743A3 (en) Hcv genomic sequences for diagnostics and therapeutics
CA2183758A1 (en) Human papilloma virus detection in a nucleic acid amplification process using general primers
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
WO1996005315A3 (en) Nucleotide and amino acid sequences of the envelope 1 and core genes of hepatitis c virus
WO2000028039A3 (en) Identification of senv genotypes
WO2004087062A3 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
WO2002053712A3 (en) Avian hepatitis e virus, vaccines and methods of protecting against avian hepatitis-splenomegaly syndrome and mammalian hepatitis e
WO2000075338A3 (en) CLONED GENONE OF INFECTIOUS HEPATITIS C VIRUS OF GENOTYPE 2a AND USES THEREOF
WO1991014779A1 (en) Diagnostic for hepatitis virus
RU2223492C2 (en) Protein obtained from neisseria meningitidis (variants, its fragment, nucleic acid encoding thereof (variants), probe, primer, composition
EP1010759A4 (en) Non-b non-c non-g hepatitis virus gene, polynucleotide, polypeptide, virion, method for separating virion, and method for detecting virus
AU2002341238A1 (en) Diabetic model
CA2198743A1 (en) Feline infectious peritonitis vaccine
Deng et al. Molecular characterization of the 11th RNA segment from human group C rotavirus
WO2003027291A3 (en) Hdv nucleic acid molecules, fragments and applications thereof
EP1312677A4 (en) Nucleic acids encoding lettuce big-vein virus proteins and utilization thereof
AU3955400A (en) The full gene sequence of the donkey leukocyte vaccine strain of the equine infectious anemia virus and their application
Pahalawatta et al. Molecular characterization of Dahlia mosaic virus and development of detection tools

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 13816

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 581206

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999971855

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09831578

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999971855

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999971855

Country of ref document: EP